Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH

Madrigal Pharmaceuticals has entered an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist and orforglipron derivative134.

Under the agreement, Madrigal will pay CSPC $120 million upfront and up to $2 billion in development, regulatory, and commercial milestone payments, plus royalties on net sales1234.

SYH2086 is in preclinical development and preclinical data indicate strong glucose-lowering and weight-loss effects in vitro and no significant safety concerns to date3.

Madrigal plans to combine SYH2086 with its foundational therapy Rezdiffra (resmetirom) for treating metabolic dysfunction-associated steatohepatitis (MASH), aiming to develop this as a once-a-day, oral combination therapy4.

Madrigal expects to complete the transaction by the end of 2025, pending regulatory clearance, with first clinical trials anticipated in early 202634.

The strategic goal is to create a best-in-class, well-tolerated oral solution for MASH, thereby extending Madrigal’s leadership and pipeline in the metabolic disease area, anchored by Rezdiffra4.

Sources:

1. https://www.ropesgray.com/en/news-and-events/news/2025/07/client-madrigal-pharmaceuticals-enters-global-license-agreement-with-cspc-pharmaceutical-group

2. https://www.biopharmadive.com/news/madrigal-buys-into-glp-1-from-cspc-apellis-wins-expanded-drug-approval/756262/

3. https://www.biospace.com/business/madrigal-makes-potential-2b-bet-for-cspcs-glp-1-pill

4. https://www.globenewswire.com/news-release/2025/07/30/3123846/0/en/Madrigal-Pharmaceuticals-Enters-into-Exclusive-Global-License-Agreement-for-Oral-GLP-1-Receptor-Agonist-with-CSPC-Pharmaceutical-Group-Limited.html